

1 **Longitudinal analysis of SARS-CoV-2 seroprevalence using multiple serology platforms**

2

3 Juan Manuel Carreño¹, Damodara Rao Mendu², Viviana Simon^{1,4,5}, Masood A Shariff³, Gagandeep

4 Singh¹, Vidya Menon^{3*}, Florian Kramer^{1*}

5

6 ¹ Dept. of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

7 ² Clinical Microbiology Laboratory, Department of Pathology, Icahn School of Medicine at Mount
8 Sinai, New York, USA

9 ³ Department of Internal Medicine, NYC Health + Hospitals/Lincoln, The Bronx, NY, USA.

10 ⁴ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai,
11 New York, NY.

12 ⁵ The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New
13 York, NY

14

15 *To whom correspondence should be addressed: menonv@nychhc.org and

16 florian.krammer@mssm.edu

17

18

19 **Abstract**

20 Serological tests are important tools helping to determine previous infection with severe acute
21 respiratory disease coronavirus 2 (SARS-CoV-2) and to monitor immune responses. The current
22 tests are based on spike (S), the receptor binding domain (RBD), or the nucleoprotein (NP) as
23 substrate. Here, we used samples from a high seroprevalence cohort of health care workers (HCWs)
24 to perform a longitudinal analysis of the antibody responses using three distinct serological assays.
25 501 serum samples were tested using: a) a research-grade RBD and spike based tandem enzyme-
26 linked immunosorbent assay (MS-RBD ELISA, MS-spike ELISA), b) a commercial RBD and spike
27 based tandem ELISA (Kantaro-RBD, -spike), and c) a commercial NP-based chemiluminescent
28 microparticle immunoassay (CMIA, Abbott Architect). Seroprevalence ranged around 28% during
29 the early stage of the pandemic (a: 28.4% positives; b: 28.1%; c: 27.3%). Good correlation was
30 observed between the MS and Kantaro RBD ELISAs and between the MS and Kantaro spike ELISAs.
31 By contrast, modest correlations were observed between the Abbott Architect and both RBD and
32 spike-based assays. A proportion of HCWs (n=178) were sampled again 3-5 months after the first
33 time point. Although antibody levels declined in most of the positive individuals, the overall
34 seroprevalence measured by RBD-spike based assays remained unchanged. However the
35 seroprevalence of NP-reactive antibodies significantly declined. Lastly, we tested six samples of
36 individuals who received two doses of SARS-CoV-2 mRNA vaccine and found that seroconversion
37 was detected by the RBD-spike assays but – of course as expected - not the NP based assay. In
38 summary, our results consolidate the strength of different serological assays to assess the
39 magnitude and duration of antibodies to SARS-CoV-2.

40

41

42

43 **Introduction**

44 In the advent of the current pandemic caused by the severe acute respiratory syndrome coronavirus
45 2 (SARS-CoV-2), pandemic, methods to detect the prevalence of recent and past infections are key
46 to determine public health and social countermeasures. Nucleic acid amplification tests (NAAT)
47 provide an accurate estimation of acute infections (1, 2), but they fail to inform about past infections.
48 Serological tests that detect antibodies directed against structural targets of the virus, not only are
49 useful to estimate the overall viral seroprevalence and rates of infection in the population (3-5), but
50 also help to assess responses to vaccination (6), to determine correlates of protection (7, 8), and to
51 test and standardize therapeutic approaches such as monoclonal antibody and plasma transfer
52 therapies (9). Moreover, estimation of viral seroprevalence and quantification of antibody levels
53 adds to our understanding of the immune response and protection at the individual and population
54 levels (10).

55
56 Currently, serological assays to detect antibodies against SARS-CoV-2 are based on recombinant
57 versions of the spike (S), the receptor binding domain (RBD) of S, or the nucleoprotein (NP) as
58 substrate (11). A variety of research grade and commercial S-based and NP-based assays are now
59 available, but antibodies to these two targets have different characteristics. Antibodies directed
60 against the viral spike are retained for several months after infection (12-17) and correlate with
61 virus neutralization and protection against re-infection (6, 13, 18-21). Moreover, vaccination relies
62 uniquely on the viral spike, evidencing the importance of detecting antibodies against this target
63 with high levels of sensitivity and specificity (6).

64
65 Several studies evaluate the sensitivity and specificity of individual assays, either S- or NP- based,
66 however longitudinal side-by-side comparisons of different serological platforms are scarce. Here,
67 we employed samples from a high-risk cohort of health care workers (HCWs) using three different
68 serological assays. In addition, SARS-CoV-2 post-vaccination samples were included in the analysis.
69 We compared a research grade RBD and spike based tandem enzyme-linked immunosorbent assay
70 (ELISA) developed at Mount Sinai (MS ELISA, research grad version), the Seroklir commercial RBD-
71 spike based ELISA from Kantaro Biosciences, and the commercial NP-based chemiluminescent
72 microparticle immunoassay (CMIA) Abbott Architect.

73

74 **Methods**

75 **Research grade ELISAs**

76 Detection of receptor binding domain (RBD) and full-length spike (S) antibodies in plasma was
77 performed with a research-grade two-step ELISA developed at Mount Sinai closely resembling an
78 assay used in Mount Sinai's CLIA-certified Clinical Pathology Laboratory, which received FDA
79 Emergency Use Authorization in April 2020 (22, 23). The research grade assay has 95% sensitivity
80 and 100% specificity (3). Before performing the ELISA, samples were heat-inactivated for 1h at
81 56°C. Briefly, for RBD screening, 96-well plates (Thermo Fisher) were coated with 50ul/well of
82 phosphate-buffered saline (PBS; Gibco) containing 2µg/ml of recombinant RBD protein and
83 incubated overnight at 4 °C. Plates were washed three times with PBS containing 0.1% Tween-20
84 (PBS-T; Fisher Scientific) using an automated plate washer (BioTek). For blocking, 200µl/well of
85 PBS-T containing 3% (w/v) of milk powder (American Bio) were added and plates were incubated
86 for 1 h at room temperature. Plasma samples were diluted (1:50) in PBS-T containing 1% milk
87 powder. Blocking solution was removed and dilutions of samples were added. After a 2-hour
88 incubation, plates were washed three times with PBS-T and 50µl/well of anti-human IgG (Fab-
89 specific) horseradish peroxidase antibody (Sigma, A0293) diluted 1:3,000 in PBS-T 1% milk powder
90 were added. Plates were incubated for 1 h at room temperature, followed by three times washing
91 with PBS-T and addition of developing solution (100µl/well) sigmafast *o*-phenylenediamine
92 dihydrochloride (Sigma). The reaction was led to proceed for 10 min, and stopped using 50µl/well
93 of 3-molar hydrochloric acid (Thermo Fisher). Optical density was measured at 490 nm using an
94 automated plate reader (BioTek). Samples with an OD_{490nm} above 0.15 (cut-off value) were
95 considered as presumptive positives and were further tested in the confirmatory ELISA using the
96 full-length recombinant spike protein.

97
98 Briefly, to perform the confirmatory ELISAs, plates were coated and blocked as described above,
99 but using full-length spike protein for coating. Presumptive positive plasma samples were serially
100 diluted (1:3) in 1%-milk prepared in PBS-T, starting at an initial dilution of 1:80. Serial dilutions
101 (100µl/well) were added to the plates, followed by 2-hour incubation at room temperature. The
102 remaining steps were performed as described above. Data was analyzed using GraphPad Prism 7.
103 Samples with an OD_{490nm} above 0.15 (cut-off value) at a 1:80 plasma dilution were considered

104 positive. Samples with an OD_{490nm} above 0.15 at the last dilution were further diluted (1:2160
105 initially) and re-tested. Only samples positive in both steps of the assay were considered positive.

106

107 **Kantaro ELISAs**

108 ELISAs to detect antibodies in plasma against the receptor binding domain (RBD) and the full-length
109 spike (S) based on the commercial Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit (COVID-
110 SeroKlir, Kantaro Biosciences) were used. The assay was performed according to manufacturer's
111 instructions except for additional serum dilution steps in highly reactive individuals. All reagents
112 and microplates were included with the commercial kit. Briefly, for qualitative RBD ELISAs, samples
113 were diluted in sample buffer (1:100) using 96-well microtitre plates, and 100µl/well of pre-diluted
114 samples were transferred to the RBD pre-coated microplates. Positive and negative controls were
115 added to every plate. Samples were incubated for 2 hours at room temperature, followed by
116 removal of plasma dilutions and washing three times with wash buffer. RBD conjugate was diluted
117 in conjugate buffer and 100µl/well were added to the plates. After 1h incubation, conjugate was
118 removed and plates were washed three times with wash buffer. Substrate solution was added
119 (100µl/well) and after 20min incubation, 100µl/well of stop solution were added. Samples were
120 read at OD_{450nm} and at OD_{570nm} for wavelength correction. The cutoff index (CI) was calculated by
121 dividing the corrected OD of the clinical sample/corrected OD of RBD positive control. Samples with
122 a CI above 0.7 were considered as presumptive positives and were further tested in the
123 confirmatory quantitative ELISA based on the full-length recombinant spike protein.

124

125 For quantitative spike ELISAs, presumptive positive plasma samples were diluted (1:200) in sample
126 buffer. Dilutions were added in duplicate to the pre-coated microplates. Low, medium and high
127 controls, as well as spike calibrators used to generate a standard curve, were added to every
128 microplates. After 2h incubation at room temperature, the remaining steps were performed as
129 described above. Data was analyzed using GraphPad Prism 7. Concentration of spike-reactive
130 antibodies was calculated using a four parameter logistic (4-PL) curve fit. Samples exceeding the
131 range of the standard curve were further diluted (1:5400) and re-tested. Only samples positive in
132 both steps of the assay were considered positive.

133

134 **Abbott Architect CMIA**

135 The Architect test (Abbott Laboratories) consists of an automated, two-step, qualitative CMIA for
136 qualitatively detecting IgG against the nucleoprotein (N) antigen from SARS-CoV-2. This test has a
137 reported sensitivity of 100% (CI 95.8–100%) and specificity of 99.6 (CI 99–99.9%) 14 days after
138 symptom onset. The assay was performed according to manufacturer’s instructions. All reagents
139 were included with the kit. Briefly, sample, SARS-CoV-2 antigen coated paramagnetic
140 microparticles, and assay diluent were combined and incubated. The IgG antibodies to SARS-CoV-2
141 present in the sample bind to the SARS-CoV-2 antigen coated microparticles. The mixture is washed.
142 Anti-human IgG acridinium-labeled conjugate is added to create a reaction mixture and incubated.
143 Following a wash cycle, Pre-Trigger and Trigger Solutions are added. The resulting
144 chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship
145 between the amount of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the
146 system optics. This relationship is reflected in the calculated Index (S/C). The presence or absence
147 of IgG antibodies to SARS-CoV-2 in the sample is determined by comparing the chemiluminescent
148 RLU in the reaction to the calibrator RLU.

149

150 **Study participants and human samples**

151 The samples used for the longitudinal study, were part of a cross sectional cohort of healthcare
152 workers (HCWs) of the New York City Public Hospital in the South Bronx. This study was approved
153 by the Institutional Review Board (IRB#20-009). Samples were collected in two phases: Phase 1
154 samples were obtained in May 2020 and Phase 2 samples were collected from August to October
155 2020. Informed consent was obtained prior to Phase 1 sample collection.

156 Samples from study participants receiving the Pfizer mRNA vaccine were obtained from IRB
157 approved longitudinal observation studies (IRB-16-00791; IRB-20-03374) conducted by the
158 Personalized Virology Initiative (PVI) at the Icahn School of Medicine at Mount Sinai. All participants
159 signed informed consents prior to data and sample collection. All serum samples were coded upon
160 collection and analyzed in a blinded manner in the Krammer laboratory.

161

162 **Statistical analysis**

163 Correlations of antibody levels in the different assays were calculated using a standard Pearson’s
164 correlation. Coefficients of correlation (r) are presented. Paired t-test for comparison of phase 1 and
165 phase 2 antibody levels was used. All adjusted P values of <0.05 were considered statistically

166 significant with a confidence interval of 95%. Statistical analyses were performed using Prism 7
167 (GraphPad, USA).

168

169 **Results**

170 **Longitudinal comparison of SARS-CoV-2 seroprevalence using RBD/spike and NP based** 171 **assays**

172 Seroprevalence of SARS-CoV-2 across different regions of the world has been described using
173 multiple serological assays based either on the spike protein (S), its receptor-binding domain (RBD),
174 or the nucleoprotein (NP). Here we compared side-by-side a research grade MS ELISA based on RBD
175 and spike, an RBD/spike based SeroKlir assay from Kantaro Biosciences and the NP based Abbott
176 Architect test. We used a set of 501 samples from frontline healthcare workers (HCW) collected
177 after the first pandemic wave in the New York City area (May 2020). Seroprevalence in this set of
178 samples using a research grade ELISA from Mount Sinai was 28.4%, (142/501), 28.1%, using the
179 SeroKlir test from Kantaro Biosciences (141/501) and 27.3% using the Abbott Architect test
180 (137/501) (**Fig. 1A**). A subset of the initial participants (n=178) attended provided a second serum
181 sample at a follow up visit in August-October 2020 allowing assessment of seroprevalence at two
182 different time points. Of note, the seroprevalence in the smaller subset of participants was higher
183 compared to the initial cohort (N=501). This is likely due to higher compliance of participants that
184 knew their sero-status in the first phase, since they were informed about their antibody levels.
185 Overall, the seroprevalence measured by the Mount Sinai and the Kantaro ELISAs did not vary
186 significantly between the two time points (**Fig. 1B-1C**), but the seroprevalence of NP reactive
187 antibodies measured by the Abbott Architect test declined (**Fig. 1D**).

188

189 We further compared the antibody levels in samples obtained during the first phase (May 2020)
190 and the second phase (Aug-Oct, 2020) in the subset of 178 subjects (the distribution of antibody
191 levels is shown in **Sup. Fig. 1** and concordance analyses among the different assays are shown in
192 **Sup. Fig. 2**). As expected, antibody levels in the second phase declined in the majority of participants
193 in a manner that was consistent in the three different assays (**Figs. 2A-2C**). A sharper decline of NP
194 reactive antibody levels as measured by the Abbott Architect test (**Fig. 2C**). Moreover, the
195 percentage of subjects that were seropositive initially and whose antibodies became undetectable
196 in the second phase did not vary significantly in the Mount Sinai and Kantaro ELISAs (**Figs. 2A-2B**)

197 but 30% of the samples that were positive initially in the Abbott Architect test became negative in
198 the second phase (**Fig. 2B**).

199 200 **Correlation of antibody levels among the different assays**

201 The antibody response against different antigenic targets of a particular virus exhibits a high degree
202 of complexity. The magnitude and kinetics of the antibody response against RBD/spike and the
203 nucleoprotein are not fully understood. To analyze the consistency between the two RBD/spike
204 based assays and to study the relationship of RBD/spike reactive antibodies versus NP reactive
205 antibodies, we performed correlation analyses among the three different assays. Using the positive
206 samples from the first (**Figs. 3A-C**) and second (**Figs. 3D-2F**) phases, we detected a good correlation
207 of RBD reactive antibodies (optical density (OD) measured at one dilution) measured by the Mount
208 Sinai ELISA versus the Kantaro ELISA either in phase 1 ($r= 0.9169$; P two-tailed= <0.0001 , **Fig. 3A**)
209 or phase 2 ($r= 0.9075$; P two-tailed= <0.0001 , **Fig. 3D**). However, the correlation of RBD reactive
210 antibodies measured in the Mount Sinai or Kantaro assays versus the NP reactive antibodies
211 measured in the Abbott Architect test, either in phase 1 (**Figs. 3B-3C**) or phase 2 (**Figs. 3E-3F**)
212 samples, was modest to low.

213 We performed next the same type of analyses but with quantitative spike reactive antibody levels
214 instead of RBD reactive antibody OD values. Again, we found a good correlation between the Mount
215 Sinai ELISA vs the Kantaro ELISA either in phase 1 ($r= 0.6860$; P two-tailed= <0.0001 , **Fig. 4A**) or
216 phase 2 ($r= 0.9135$; P two-tailed= <0.0001 , **Fig. 4D**) and a weak correlation between spike reactive
217 antibodies measured in the Mount Sinai or Kantaro assays versus the NP reactive antibodies
218 measured in the Abbott Architect test (**Figs. 4B-4C**: phase 1; **Figs. 4E-4F**: phase 2). For both RBD
219 and spike, some of the subjects exhibited very high levels of RBD reactive antibodies and low levels
220 of NP reactive antibodies and *vice versa*. Overall, these findings indicate that the magnitude of
221 RBD/spike and NP antibody responses differs considerably highlighting the need for further studies
222 using samples from well-described longitudinal cohort studies.

223 224 225 226 **Detection of vaccine induced antibodies in both assays**

227 To date only limited data is available about how commercial antibody assays respond to antibodies
228 developed in response to vaccination. In order to determine how the three assays perform against
229 vaccine-induced antibodies, we measured reactivity in serum of individuals who had received two
230 doses of SARS-CoV-2 mRNA vaccines. The expectation was, that the RBD/spike based assays would
231 detect a signal while the NP based assay would not. Indeed, we measured high titers using the Spike
232 based assay platforms (the Mount Sinai and Kantaro assays) but the samples produced no signal in
233 the NP-based assay (**Fig. 5A-5C**). Of note, the spike titers measured in the Mount Sinai and Kantaro
234 assay correlated very well (**Fig. 5D**).

235

236 **Discussion**

237 While antibody responses to acute SARS-CoV-2 infection are relatively well understood, less data is
238 available regarding antibody kinetics over longer time frames against different viral antigens. We
239 determined seroprevalence and antibody titers in SARS-CoV-2 infected individuals at two time
240 points (1-2 months and 3-4 months post infection) using three different assays. One assay, the
241 Mount Sinai ELISA, is a laboratory-developed assay that uses an initial ELISA at a single serum
242 dilution against the RBD followed by a confirmation and titration against the full-length spike
243 protein. The second assay tested, the Kantaro SeroKlir assay, is based on the same principle, but
244 commercially available. The third assay, the Abbott Architect, targets the NP and is a CMIA.

245 There was high concordance among the three assays with respect to seroprevalence during phase
246 1. However, the titers only correlated well for the two spike-based assays. During phase 2, the two
247 spike-based assays identified all (Mount Sinai Research grade) or the vast majority (Kantaro) of
248 previously seropositive individuals as seropositive, while the NP based assay (Abbott) failed to
249 detect a signal above the cut-off in approximately 30% of previously positive individuals. These
250 findings mirror similar results recently published by Grandjean and colleagues, suggesting that the
251 NP antibody response is short-lived (24). However, it could also be a reflection of a high cut-off
252 required to ensure high specificity for SARS-CoV-2 in the NP-based assay. Importantly, and as
253 expected since no NP is included in the FDA EUA approved vaccines used in the US, only the spike-
254 based assays were able to detect antibodies induced by SARS-CoV-2 mRNA vaccines (6). Our data
255 highlight the need to understand assay performance before a specific assay is used to study specific
256 aspects of SARS-CoV-2 immunity. All three assays are very valuable to assess seroconversion
257 shortly after infection, but only the two spike-based assays were reliable months after recovery.

258 Similarly, only spike-based assays are fit for measuring vaccine-induced antibodies, e.g. to
259 determine if vaccination triggered immune responses.

260

261 **Acknowledgements**

262 We thank the study participants for their continued generosity and willingness to support our
263 longitudinal studies and our colleagues Adolfo Firpo and Carlos Cordon-Cardo for supporting our
264 collaborative serology work. We also acknowledge the continued efforts of the Personalized
265 Virology Initiative (in alphabetical order: Bulbul Ahmed, Hala Alshammary, Angela Amoako,
266 Mahmoud Awawda, Katherine Beach, Carolina Bermúdez-González, Rachel Chernet, Lily Eaker,
267 Shelcie Fabre, Emily. D. Ferreri, Daniel Floda, Charles Gleason, Dr. Giulio Kleiner, Dr. Denise
268 Jurczynszak, Julia Matthews, Wanní Mendez, Dr. Lubbertus CF Mulder, Jose Polanco, Kayla Russo,
269 Ashley Salimbangon, Dr. Miti Saksena, A. Shin, Levy Sominsky, Komal Srivastava, Sayahi
270 Suthakaran). We thank research associates for their assistance with sample processing at Lincoln
271 Hospital: Dominika Bielak, Ajmal Khan and Syed Hamad Ali Shah. Work in the Krammer and the
272 Simon laboratories is partially funded by the NIAID Collaborative Influenza Vaccine Innovation
273 Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and
274 Surveillance (CEIRS, contract # HHSN272201400008C), by the generous support of the JPB
275 Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by
276 anonymous donors. This effort was also supported by the Serological Sciences Network (SeroNet)
277 in part with Federal funds from the National Cancer Institute, National Institutes of Health, under
278 Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication
279 does not necessarily reflect the views or policies of the Department of Health and Human Services,
280 nor does mention of trade names, commercial products or organizations imply endorsement by the
281 U.S. Government.

282

283 **Conflict of interest statement**

284 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2
285 serological assays (the “Serology Assays”) and NDV-based SARS-CoV-2 vaccines which list
286 Florian Krammer (the “Serology Assays”, vaccines) and Viviana Simon (“Serology Assays”) as co-
287 inventors. The foundational “Serology Assay” intellectual property (IP) was licensed by the Icahn
288 School of Medicine at Mount Sinai to commercial entities including Kantaro Biosciences, a

289 company in which Mount Sinai has a financial interest. Kantaro manufactures and markets
290 serologic tests based on the Mount Sinai IP. It is anticipated that the medical school will receive
291 payments related to commercialization of the “Serology Assay” IP and, as faculty inventors, Drs.
292 Krammer and Simon will be entitled to a portion of these payments.
293 Florian Krammer consulted for Merck, Curevac and Pfizer in the past (before 2020) and is
294 currently consulting for Pfizer, Seqirus and Avimex. The Krammer laboratory is collaborating with
295 Pfizer on animal models of SARS-CoV-2.

296

297 **References:**

298

- 299 1. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. 2020. Viral load of SARS-CoV-2 in clinical
300 samples. *Lancet Infect Dis* 20:411-412.
- 301 2. Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, Ng DYM, Wan CKC, Yang P, Wang Q,
302 Peiris M, Poon LLM. 2020. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing
303 an Outbreak of Pneumonia. *Clin Chem* 66:549-555.
- 304 3. Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA,
305 McMahan M, Capuano C, Twyman K, Jhang J, Nowak MD, Simon V, Sordillo EM, van Bakel H,
306 Krammer F. 2020. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York
307 City. *Nature*.
- 308 4. Rostami A, Sepidarkish M, Leeftang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S,
309 Mokdad AH, Hotez PJ, Gasser RB. 2020. SARS-CoV-2 seroprevalence worldwide: a systematic
310 review and meta-analysis. *Clin Microbiol Infect*.
- 311 5. Angulo FJ, Finelli L, Swerdlow DL. 2021. Estimation of US SARS-CoV-2 Infections,
312 Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA*
313 *Netw Open* 4:e2033706.
- 314 6. Krammer F. 2020. SARS-CoV-2 vaccines in development. *Nature* 586:516-527.
- 315 7. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo
316 C, Zhu A, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Li Z, Nampanya F, Patel S, Pessaint
317 L, Van Ry A, Blade K, Yalley-Ogunro J, Cabus M, Brown R, Cook A, Teow E, Andersen H, Lewis
318 MG, Lauffenburger DA, Alter G, Barouch DH. 2020. Correlates of protection against SARS-
319 CoV-2 in rhesus macaques. *Nature*.
- 320 8. Brown M. 2020. Immune correlates of SARS-CoV-2 protection. *Nat Rev Immunol* 20:593.
- 321 9. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang
322 J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin
323 L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng
324 X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. 2020.
325 Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad*
326 *Sci U S A* 117:9490-9496.
- 327 10. Cohen MS. 2021. Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.
328 *N Engl J Med* 384:289-291.
- 329 11. Krammer F, Simon V. 2020. Serology assays to manage COVID-19. *Science* 368:1060-1061.

- 330 12. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier
331 A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM,
332 Weiskopf D, Sette A, Crotty S. 2020. Immunological memory to SARS-CoV-2 assessed for up
333 to eight months after infection. *bioRxiv*.
- 334 13. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P,
335 Mendu DR, Muellers K, Stadlbauer D, Stone K, Strohmeier S, Simon V, Aberg J, Reich DL,
336 Krammer F, Cordon-Cardo C. 2020. Robust neutralizing antibodies to SARS-CoV-2 infection
337 persist for months. *Science* 370:1227-1230.
- 338 14. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang YM, Pu A,
339 Christie-Holmes N, Gervais C, Ceccarelli D, Samavarchi-Tehrani P, Guvenc F, Budylowski P,
340 Li A, Paterson A, Yue FY, Marin LM, Caldwell L, Wrana JL, Colwill K, Sicheri F, Mubareka S,
341 Gray-Owen SD, Drews SJ, Siqueira WL, Barrios-Rodiles M, Ostrowski M, Rini JM, Durocher Y,
342 McGeer AJ, Gommerman JL, Gingras AC. 2020. Persistence of serum and saliva antibody
343 responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol* 5.
- 344 15. Iyer AS, Jones FK, Nodoushania A, Kelly M, Becker M, Slater D, Mills R, Teng E, Kamruzzaman
345 M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oiver E, Fischinger S, Atyeo C, Iafrate
346 AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Cardonna TM, Branda JA,
347 Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS, Alter G, Ryan ET,
348 Harris JB, Charles RC. 2020. Dynamics and significance of the antibody response to SARS-
349 CoV-2 infection. *medRxiv:2020.07.18.20155374*.
- 350 16. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y,
351 Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered
352 patient cohort and their implications. *medRxiv:2020.03.30.20047365*.
- 353 17. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, Hemmings O, O'Byrne A,
354 Kouphou N, Galao RP, Betancor G, Wilson HD, Signell AW, Winstone H, Kerridge C, Huettnner
355 I, Jimenez-Guardeño JM, Lista MJ, Temperton N, Snell LB, Bisnauthsing K, Moore A, Green A,
356 Martinez L, Stokes B, Honey J, Izquierdo-Barras A, Arbane G, Patel A, Tan MKI, O'Connell L,
357 O'Hara G, MacMahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Shankar-Hari M,
358 Edgeworth JD, Neil SJD, Malim MH, Doores KJ. 2020. Longitudinal observation and decline of
359 neutralizing antibody responses in the three months following SARS-CoV-2 infection in
360 humans. *Nat Microbiol* 5:1598-1607.
- 361 18. Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H,
362 Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin C.
363 2020. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.
364 *Science* 369:818-823.
- 365 19. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski LH, Yu J,
366 Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S, Martinez DR, Atyeo C,
367 Fischinger S, Burke JS, Slein MD, Pessaint L, Van Ry A, Greenhouse J, Taylor T, Blade K, Cook
368 A, Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P, Bondzie EA,
369 Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifton MA, Mahrokhian SH,
370 Maxfield LF, Nityanandam R, Nkolola JP, Schmidt AG, Miller AD, Baric RS, Alter G, Sorger PK,
371 Estes JD, et al. 2020. SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
372 *Science* 369:812-817.
- 373 20. Hall V, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, Wellington E, Cole MJ, Saei A,
374 Oguti B, Munro K, Wallace S, Kirwan PD, Shrotri M, Vusirikala A, Rokadiya S, Kall M, Zambon
375 M, Ramsay M, Brooks T, Brown CS, Chand MA, Hopkins S. 2021. Do antibody positive

- 376 healthcare workers have lower SARS-CoV-2 infection rates than antibody negative
377 healthcare workers? Large multi-centre prospective cohort study (the SIREN study),
378 England: June to November 2020. medRxiv:2021.01.13.21249642.
- 379 21. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox
380 S, James T, Warren F, Peck LJ, Ritter TG, de Toledo Z, Warren L, Axten D, Cornall RJ, Jones EY,
381 Stuart DI, Sreaton G, Ebner D, Hoosdally S, Chand M, Crook DW, O'Donnell AM, Conlon CP,
382 Pouwels KB, Walker AS, Peto TEA, Hopkins S, Walker TM, Jeffery K, Eyre DW, Group OUHST.
383 2020. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl*
384 *J Med*.
- 385 22. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahan M, Jiang K,
386 Arunkumar GA, Jurczynszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin
387 L, Fierer DS, Lugo LA, Kojic EM, Stoeber J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran
388 T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V,
389 Krammer F. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat*
390 *Med*.
- 391 23. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar
392 D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahan M, Simon V, Krammer F.
393 2020. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay,
394 Antigen Production, and Test Setup. *Curr Protoc Microbiol* 57:e100.
- 395 24. Grandjean L, Saso A, Torres A, Lam T, Hatcher J, Thistlethwayte R, Harris M, Best T, Johnson
396 M, Wagstaffe H, Ralph E, Mai A, Colijn C, Breuer J, Buckland M, Gilmour K, Goldblatt D. 2020.
397 Humoral Response Dynamics Following Infection with SARS-CoV-2.
398 medRxiv:2020.07.16.20155663.
399

400

401 **Figure legends**

402 **Figure 1. Seroprevalence against SARS-CoV-2 in healthcare workers using different serology**
403 **platforms.** Serum samples from frontline healthcare workers were assessed for antibodies against
404 RBD-Spike using a research grade ELISA from Mount Sinai, against RBD-Spike using a commercial
405 ELISA from Kantaro Biosciences, or against NP using Abbott-Architect CMIA. Initially, samples
406 analyzed in the three assays consisted of specimens obtained early during the pandemic on May
407 2020 (n=501) (A). Seroprevalence in a subset of subjects (n=178) who attended a follow up visit on
408 August-October 2020 was determined using the three different serological assays and a comparison
409 of the two time points is shown (B-C).

410

411 **Figure 2. Longitudinal analysis of antibody levels against RBD-Spike or NP in seropositive**
412 **subjects.** Serum samples from frontline healthcare workers were obtained on May 2020 or August-
413 October 2020. Antibodies against RBD-Spike were measured using a research grade ELISA from

414 Mount Sinai (A); against RBD-Spike using a commercial ELISA from Kantaro Biosciences (B); or
415 against NP using the Abbott-Architect CMIA (C). Antibody levels in specimens obtained early during
416 the pandemic on May 2020 or in a follow up visit on August-October 2020 are shown. Samples with
417 a value above or below the cutoff of the corresponding assay (dotted line) are shown. **** P<0.0001.
418 The percentage of seropositive samples that turned negative (red) or that remained positive (blue)
419 as measured in each of the corresponding assays is shown in D-F.

420

421 **Figure 3. Correlation analysis of antibody levels (RBD-reactive) among the different serology**
422 **assays.** Serum samples were assessed for antibodies against RBD-Spike using a research grade
423 ELISA from Mount Sinai, against RBD-Spike using a commercial ELISA from Kantaro Biosciences or
424 against NP using the Abbott-Architect CMIA. Correlation of antibody levels (RBD reactive) among
425 the different assays using serum samples obtained on May 2020 (first time point) is shown (A-C).
426 Correlation of antibody levels (RBD reactive) among the different assays using serum samples
427 obtained on August-October 2020 (second time point) is shown (D-F). Correlation analysis between
428 Mount Sinai RBD and Kantaro RBD ELISAs (A, D); between Mount Sinai RBD and Abbott Architect
429 NP ELISAs (B, E); and between Kantaro RBD ELISAs and Abbott Architect NP CMIA (C, F) are
430 shown. Pearson correlation was used. Significance and coefficient of determination are shown.

431

432 **Figure 4. Correlation analysis of antibody levels (spike-reactive) among the different**
433 **serology assays.** Serum samples were assessed for antibodies against RBD-Spike using a research
434 grade ELISA from Mount Sinai, against RBD-Spike using a commercial ELISA from Kantaro
435 Biosciences or against NP using the Abbott-Architect CMIA. Correlation of antibody levels (spike
436 reactive) among the different assays using serum samples obtained on May 2020 (first time point)
437 is shown (A-C). Correlation of antibody levels (spike reactive) among the different assays using
438 serum samples obtained on August-October 2020 (second time point) is shown (D-F). Correlation
439 analysis between Mount Sinai RBD and Kantaro RBD ELISAs (A, D); between Mount Sinai RBD and
440 Abbott Architect NP CMIA (B, E); and between Kantaro RBD ELISAs and Abbott Architect NP CMIA
441 (C, F) are shown. Pearson correlation was used. Significance and coefficient of determination are
442 shown.

443

444 **Figure 5. Post SARS-CoV-2 mRNA vaccination serum titers as measured in three different**
445 **assays.** Serum samples of individuals who had received two doses of SARS-CoV-2 mRNA vaccines
446 were assessed for antibodies against RBD-spike using a research grade ELISA from Mount Sinai (A),
447 against RBD-spike using a commercial ELISA from Kantaro Biosciences (B) or against NP using the
448 Abbott-Architect CMIA (C). Correlation of antibody levels (spike reactive) between the Mount Sinai
449 ELISA and the commercial ELISA from Kantaro Biosciences assays using the same serum samples
450 (D).

451
452 **Supplementary Figure 1. Distribution of antibody levels (spike-reactive) in the different**
453 **serology platforms.** Serum samples were assessed for antibodies against RBD-Spike using a
454 research grade ELISA from Mount Sinai (A, D), against RBD-Spike using a commercial ELISA from
455 Kantaro Biosciences (B, E), or against NP using the Abbott-Architect ELISA (C, F). Distribution of
456 antibody levels (spike-reactive) early during the pandemic on May 2020 (A-C) or in August-October
457 2020 (D-E) are shown.

458
459 **Supplementary Figure 2. Concordance analysis of positive samples among the different**
460 **serology assays.** Venn diagrams depicting the number of seropositive samples measured by a RBD-
461 Spike research grade ELISA from Mount Sinai (blue); a RBD-Spike commercial ELISA from Kantaro
462 Biosciences (red), or an Abbott-Architect NP ELISA (green). Concordance of positivity among the
463 three different assays using samples obtained early during the pandemic on May 2020 is shown (A).
464 Seroprevalence in a subset of subjects (n=178) who attended a follow up visit on August-October
465 2020 was determined using the three different serological assays. Concordance of positivity in that
466 subset of subjects on May 2020 (B) or August-October 2020 (C) is shown.

467

Figure 1






Figure 2


A




B




C



D



E



F




Figure 3




Figure 4






Figure 5


A




B




C



D




Supplementary figure 1




Supplementary figure 2

A



B



C

